ACTengine® IMA203 Combined With mRNA-4203
Phase 1
15
about 4.1 years
18+
4 sites in CA, MA, NY +1
About this study
This trial is testing the safety, tolerability, and anti-tumor activity of IMA203 when combined with different doses of mRNA-4203. It includes adults who have previously been treated for unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive IMA203
- 2.Receive mRNA-4203
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants with dose-limiting toxicities (DLTs), Number of treatment emergent adverse events (AEs), AEs of special interest, serious AEs (SAEs), changes in laboratory parameters and vital signs, and frequency of dose interruptions, reductions and discontinuations
Secondary: Disease control rate (DCR), Duration of response (DOR), Objective response rate (ORR), Progression-free survival (PFS)
Oncology